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Abstract 
Background. It is recommended to perform atrial fibrillation ablation with continuous 
anticoagulation. Continuous apixaban has not been tested. 
Methods. We compared continuous apixaban (5 mg BD) to vitamin K antagonists (VKA, INR 2-3) in 
atrial fibrillation patients at risk of stroke a prospective, open, multi-center study with blinded outcome 
assessment. Primary outcome was a composite of death, stroke, or bleeding (BARC 2-5). A high-
resolution brain magnetic resonance imaging (MRI) sub-study quantified acute brain lesions. Cognitive 
function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and at end of follow-up.  
Results. Overall, 674 patients (median age 64 years, 33% female, 42% non-paroxysmal atrial 
fibrillation, 49 sites) were randomized; 633 received study drug and underwent ablation; 335 undertook 
MRI (25 sites, 323 analyzable scans). The primary outcome was observed in 22/318 patients randomized 
to apixaban, and in 23/315 randomized to VKA (difference -0.38% [90% CI -4.0%, 3.3%], non-inferiority 
p=0.0002 at the pre-specified absolute margin of 0.075), including 2 (0.3%) deaths, 2 (0.3%) strokes, 
and 24 (3.8%) ISTH major bleeds. Acute small brain lesions were found in a similar number of patients 
in each arm (apixaban 44/162 (27.2%); VKA 40/161 (24.8%); p=0.64). Cognitive function increased at 
the end of follow-up (median 1 MoCA unit, p=0.005) without differences between study groups.  
Conclusions. Continuous apixaban is safe and effective in patients undergoing atrial fibrillation 
ablation at risk of stroke with respect to bleeding, stroke, and cognitive function. Further research is 
needed to reduce ablation-related acute brain lesions. Funding: AFNET, DZHK, BMS/Pfizer; AXAFA-
AFNET 5; NCT02227550.  
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Introduction 
Catheter ablation is an effective1-3 and increasingly used component of rhythm control therapy to 
improve symptoms in patients with atrial fibrillation.4-6 Atrial fibrillation ablation is associated with a 
risk of stroke and major bleeding.4-6 Continuous oral anticoagulation using vitamin K antagonists (VKA) 
such as warfarin can reduce the risk of embolic events to less than 1% when combined with peri-
procedural heparin.7 Therefore, continuous oral anticoagulation is recommended in patients 
undergoing atrial fibrillation ablation.4, 6, 7 One randomized trial comparing rivaroxaban to warfarin in 
218 patients found similar bleeding rates with rivaroxaban compared to warfarin: 21/114 (18.4%) 
patients with bleeding on rivaroxaban, 18/104 (17.3%) patients with bleeding on VKA, one patient with 
stroke.8 Another trial randomizing 635 atrial fibrillation ablation patients to dabigatran or VKA found 
59/318 (18.6%) patients with bleeding on dabigatran, 54/317 (17%) patients with bleeding on VKA, and 
one patient with transient ischemic attack.9 Continuous apixaban has not been compared to VKA in 
atrial fibrillation ablation patients. 
Atrial fibrillation ablation, unlike other ablation procedures, has been associated with declining 
cognitive function 90 days after the procedure, raising concerns about peri-procedural protection of the 
brain.10, 11 Furthermore, acute brain lesions without corresponding neurological symptoms are detected 
in ca. 25% of patients undergoing atrial fibrillation ablation by high resolution diffusion weighted brain 
magnetic resonance imaging (MRI), a sequence that detects acute cytotoxic brain edema.12-15 Cognitive 
function and acute brain lesions have not been evaluated in controlled clinical trials of patients 
undergoing atrial fibrillation ablation. 
 
Objectives 
Therefore, we conducted a randomized trial comparing continuous apixaban to continuous VKA therapy 
in patients undergoing atrial fibrillation ablation, including assessment of cognitive function in all 
patients and MRI-detected brain lesions in a sub-study. 
 
Trial design 
AXAFA – AFNET 5 (Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial 
Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy) was an investigator-
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initiated, prospective, parallel-group, randomized, open, blinded outcome assessment study comparing 
continuous apixaban therapy to vitamin K antagonist therapy. Details of the study design have been 
published.16 AXAFA – AFNET 5 was conducted in Europe and North America. The trial sponsor was 
AFNET, Münster, Germany (www.kompetenznetz-vorhofflimmern.de). AXAFA – AFNET 5 was 
designed by the steering committee in cooperation with AFNET and conducted in accordance with the 
declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice 
Guidelines (ICH-GCP). The protocol was approved by ethical review boards at all institutions. The 
Clinical Research Institute (CRI, Munich, Germany) executed the study in cooperation with the steering 
committee and the sponsor. Data collection and entry was performed using the MARVIN® eCRF 
system.16-18 An independent steering committee and an independent data and safety monitoring board 
guided the trial. All serious adverse events were adjudicated by an independent endpoint review 
committee blind to study group and INR values. The Duke Clinical Research Institute served as the 
statistical core and performed the statistical analyses for the trial. The authors vouch for the accuracy 
and completeness of the data and for the fidelity of the trial to the protocol. This manuscript was written 
by the authors. 
 
Study Population 
AXAFA – AFNET 5 enrolled patients scheduled for a first atrial fibrillation ablation. Patients had at least 
one established stroke risk factor (age≥75 years, heart failure, hypertension, diabetes, or prior stroke). 
The full inclusion and exclusion criteria have been published (see Table 1).16  
 
Treatment 
At baseline, clinical parameters, stroke risk, heart rhythm, symptoms, quality of life (EQ-5D, SF-121, and 
Karnofsky performance status18), and cognitive function (Montreal Cognitive Assessment Test 
(MoCA))19 were assessed. Patients were randomized in a ratio of 1:1 to apixaban or vitamin K antagonist 
therapy (VKA). Randomization was stratified by study site and AF type (paroxysmal vs. persistent or 
long-standing persistent). The randomization scheme was generated via a computer program using 
permuted block of a random size.   
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Apixaban. Patients randomized to apixaban received 5 mg twice daily throughout the study period. 
The apixaban dose was reduced to 2.5 mg twice daily if two or more of the following characteristics were 
present: age 80 years, body weight ≤60 kg, or serum creatinine level 1.5 mg/dL (133 μmol/L).16, 20 
Apixaban was continued during the ablation procedure without interruption, including on the morning 
of ablation. Continuous anticoagulation in this group was defined as having taken all but one apixaban 
dose per week based on pill count.  
 
VKA. Patients randomized to VKA were treated using the locally used VKA, e.g. warfarin, 
phenprocoumon, or acenocoumarol21, prescribed and dispensed following local routine. VKA therapy 
was monitored by international normalized ratio (INR) measurements; a minimum of three INR 
measurements was mandatory prior to ablation. The last INR prior to ablation needed to be 1.8 or 
higher. The time in the therapeutic range was calculated by the Rosendaal method.22 Continuous 
anticoagulation in this group was defined by therapeutic INR (INR ≥2) in all INR measurements 30 
days prior to catheter ablation. 
 
All patients underwent follow-up visits at the time of the ablation procedure and 3 months after ablation. 
At the ablation visit, continuous anticoagulation for at least 30 days prior to ablation was assessed and 
an ECG performed. Transesophageal echocardiography could be used following local practice. 
Interrupted anticoagulation required rescheduling of the ablation for 30 days unless (1) atrial thrombi 
were excluded by transesophageal echocardiogram and (2) effective anticoagulation was demonstrated 
prior to starting the ablation procedure by either taking at least two doses of apixaban (patients 
randomized to apixaban), or by an INR value ≥1.8 (patients randomized to VKA). A heparin bolus (100 
IU/kg body weight) was required prior to or directly after transseptal puncture. The ablation procedure 
followed local practice and current guidelines.4-6 The protocol encouraged pulmonary vein isolation, the 
use of irrigated tip catheters, and flushing of all left atrial sheaths. Activated Clotting Time (ACT) was 
kept >300 s throughout the procedure. ACT measurements, details of the ablation technology used, 
delivered energy, procedure time, rhythm at beginning and end of procedure, and the need for 
cardioversion during the procedure were collected. An echocardiogram (transthoracic or intracardiac) 
was mandated directly after ablation to detect pericardial effusion.  
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At the 3 month visit, cognitive function and quality of life were reassessed, a 24 hour Holter ECG was 
performed, and study medication was returned. A final phone call to assess serious adverse events was 
performed 30 days after discontinuation of study drug. 
 
MRI sub-study 
Centres participating in the MRI sub-study (n=25) offered brain MRI to all eligible study patients. A 
brain MRI was performed within 48 hours after the ablation procedure. The MRI sequences were 
designed to detect all acute brain lesions, and to differentiate acute from chronic lesions. An imaging 
charta defined the MRI and adjudication workflow and brain MRI requirements (supplementary 
table 2). The following MRI-sequences were used: T2*-weighted imaging to screen for intracranial 
hemorrhage, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps (post 
processed) to assess acute brain infarction, and Fluid-attenuated inversion recovery (FLAIR) to 
investigate the age of brain lesions.14, 15  DWI was conducted using a slice thickness of 2.5-3 mm (high 
resolution DWI) to enhance the sensitivity of MRI for small lesions.14, 15   Images failing the immediate 
quality check were repeated whenever feasible. All images were independently analyzed by two 
experienced neuro-radiologists blinded to treatment allocation.  
 
Study Outcomes  
The primary outcome measured from randomization was the composite of all-cause death, stroke, or 
major bleeding among modified intention-to-treat (mITT) population, defined as all randomized 
patients who received study drug and underwent catheter ablation. Safety was assessed in all randomized 
patients receiving study drug (safety population). Sensitivity analyses were performed in all randomized 
patients (ITT). Another sensitivity analysis compared events during the peri-ablation period defined 
from ablation to 7 days after the procedure.9 Major bleeding was defined according to the Bleeding 
Academic Research Consortium (BARC≥2).23 All bleeding events were centrally adjudicated according 
to the BARC, ISTH, and TIMI classifications.23, 24 
Secondary Outcomes included time from randomization to ablation (ITT population), nights spent in 
hospital after ablation, activated clotting time (ACT) during ablation (summarized as median, 25th,  75th 
percentiles, and number of ACT measurements within the target range), all bleeding events, tamponade, 
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need for transfusion, and changes in quality-of-life and cognitive function compared to baseline. In the 
MRI sub-study, the prevalence and number of MRI-detected acute brain lesions were compared 
between groups.  
 
Adverse events  
All serious adverse events were collected, defined as adverse events that caused or prolonged 
hospitalization, caused disability or incapacity, were life-threatening, resulted in death or were 
important medical events. In addition, pregnancy, overdose, and cancer diagnosed after randomization 
were defined as serious adverse events. As AXAFA – AFNET 5 compared approved anticoagulants 
within their indications, non-serious adverse events were generally not reported, but those of special 
interest were defined and assessed. These comprised ablation-related complications including non-
serious bleeding. The protocol encouraged brain imaging in patients who developed neurological 
abnormalities after the ablation procedure. All events from randomization to 3 months after index 
ablation procedure or to premature study termination were analyzed. 
 
Statistical analysis  
We estimated that a total of 650 patients (325 per group) were needed to detect a pre-specified margin 
of 7.5% (absolute difference) with 80% power using upper 1-sided 95% confidence interval (i.e., 2-sided 
90% CI) with 3% attrition rate. The Farrington and Manning score test was used to compute sample size 
and power. The primary non-inferiority hypothesis was tested in the ablation population (mITT) using 
the method of Farrington and Manning score test with the pre-specified absolute margin of 0.075. In 
addition, a time-to-event analysis using Cox proportional hazards model with a relative margin of 1.44 
was conducted. A multivariable Cox proportional hazards model controlling for the baseline risk factors 
of age, sex, weight, type of atrial fibrillation, and the CHADS2 factors was conducted. Changes in quality 
of life and cognitive function were assessed at 3 months compared to baseline using the EQ-5D and SF-
12 questionnaires, Montreal Cognitive Assessment, and Karnofsky scale. Changes in quality of life were 
compared by Analysis of Covariance (ANCOVA) models including the treatment arms as an indicator 
variable and the baseline quality-of-life variables as covariates. To accrue sufficient events for a formal 
non-inferiority analysis, AXAFA – AFNET 5 was exclusively conducted in patients at risk of stroke 
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(Table 1) and counted bleeding events following the relatively broad BARC classification.23 An 
independent data and safety monitoring board monitored the study for safety. The Haybittle–Peto 
boundary was used as stopping rule guidance.  
Descriptive statistics for continuous and categorical variables were summarized as means (SDs) and 
medians (25th, 75th percentiles), and numbers (percentages), respectively. Comparisons between 
continuous variables were performed using the Wilcoxon rank-sum test or two-sample t-test depending 
on normality; comparisons between nominal variables were performed using the Pearson’s chi-square 
test or Fisher’s exact test, depending on expected cell sizes. All analyses were 2-sided and tested at the 
nominal 0.05 significance level. No adjustment was made for multiple testing. Statistical analyses were 
performed with SAS version 9.4 (SAS Institute Inc., Cary, NC).  
 
Results 
Trial Participants 
AXAFA – AFNET 5 randomized 674 patients across 49 sites in 9 countries from February 2015 to April 
2017. Overall, 633 patients took study drug and underwent atrial fibrillation ablation (mITT, ablation 
set, Figure 1). Demographic and clinical characteristics were well balanced between groups (Table 1). 
Transesophageal echocardiography was used in 549/633 (86.7%) patients. All or all but one apixaban 
doses per week were taken by 307/318 (97%) patients randomized to apixaban in the ablation set. The 
median time in therapeutic range in the 315 patients randomized to VKA in the ablation set was 84% ( 
71, 97%). Time from randomization to ablation was not different between study groups (Table 1).  
 
Primary outcome 
Primary outcome events (BARC 2-5 bleeding, stroke, or death) were observed in 22/318 (6.9%) patients 
randomized to apixaban, and in 23/315 (7.3%) patients randomized to vitamin K antagonist therapy in 
the ablation set. Four events were classified as TIMI major bleeding, and 24 events are ISTH major 
bleeding (Table 3). Two patients died: one patient randomized to VKA, female, age 70, hypertensive, 
last blood pressure 156/76, last INR 2.6, underwent pacemaker implantation 8 days after ablation and 
experienced a massive intracerebral haemorrhage. Another patient randomized to apixaban, male, age 
69, with paroxysmal atrial fibrillation, hypertension, heart failure, diabetes, and chronic obstructive 
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lung disease, was found dead in his bed 19 days after ablation without identifiable cause of death upon 
autopsy. Two patients randomized to apixaban had a stroke. Both had persistent AF and underwent 
transesophageal echocardiogram. One patient, male, age 63, hypertensive, ACT 236-398s, developed 
slurred speech with matching MRI lesion on the day of radiofrequency pulmonary vein isolation that 
fully resolved. Another patient, male, age 52, ACT 301-400s, hypertensive, developed weakness of the 
right arm with paresthesia of the right leg after cryo-balloon pulmonary vein isolation that persisted 
beyond hospital discharge. Tamponade occurred in 2 (apixaban) and 5 (VKA) patients and was managed 
by pericardial drainage and administration of protamine and vitamin K. One patient with tamponade in 
each study group received blood transfusions. Anticoagulants were continued in five patients with 
tamponade, and paused for 4 days in one patient randomized to apixaban, and for 8 days in one patient 
randomized to VKA. All patients were discharged from hospital and attended the 3 months follow up 
(n=6) or an end of study visit (n=1). 
Apixaban was noninferior to VKA based on the non-inferiority margin of 7.5% (a difference of -0.38%, 
90% confidence interval -4.0%, %-3.3%, non-inferiority p=0.0002). Apixaban was also noninferior to 
VKA among all randomized patients as assessed by Cox proportional hazards model comparison 
between treatment groups using a relative non-inferiority margin of 1.44 (equivalent to 7.5% absolute;  
hazard ratio=0.88, 90% CI 0.55, 1.41, p=0.042, Figure 2). There was no statistical interaction between 
clinical stroke and bleeding risk factors and treatment groups (Figure 3). 
 
Secondary outcome parameters 
There was no difference in time to ablation or nights spent in hospital after the ablation between groups 
(Table 4). As expected, the last INR prior to ablation and activated clotting times achieved during 
ablation were lower in the patients randomized to apixaban (Table 4).  Quality of life as assessed by the 
physical component of SF-12 (+2.5 (-2.1, 8.1) units) and Karnofsky scale (+10 (0,10)) improved during 
the study without differences between study groups (Table 4). At least mild cognitive dysfunction was 
found in 188/619 (30.4%) of the patients at baseline (pre-defined as MoCA<26, Table 2). At the end of 
follow-up, MoCA increased by a median of +1.0 (-1.0, 2.0) unit without differences between study 
groups, and 7.2% fewer patients had mild cognitive impairment (Table 4). 
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MRI sub-study  
Acute brain MRI was performed in 335 patients across 25 centres. Clinical characteristics of the sub-
study population were not different from the main study population, with the exception of a lower 
median weight in patients undergoing MRI (85.0 kg (74.5, 96.0)) compared to non-MRI patients (90.0 
kg (80.0, 103.0)). Clinical characteristics were well balanced between MRI sub-study treatment groups. 
There were 323 analyzable MRIs. Acute brain MRI lesions (Figure 4) were found in 44/162 (27.2%) 
patients randomized to apixaban, and in 40/161 (24.8%) patients randomized to VKA (p=0.635), with 
very similar distribution of lesions between random groups (Table 5). Cognitive function at the end of 
follow-up was not different in patients with or without acute brain lesions (MoCA 27.1±2.7 in 239 
patients without MRI lesions, 27.1±2.8 in 84 patients with MRI lesions, p=0.91).  
 
Discussion 
AXAFA – AFNET 5 demonstrated that continuous anticoagulation with apixaban is a safe and effective 
alternative to VKA in patients at risk of stroke undergoing atrial fibrillation ablation. AXAFA – AFNET 
5 observed 4 TIMI major bleeding events in 633 patients (0.6%, Table 3) compared to 1 event in 248 
patients in VENTURE-AF (0.4%)8. AXAFA – AFNET 5 observed 24 patients with ISTH major bleeding 
events (3.8%, Table 3) compared to 27 events in 635 patients in RE-CIRCUIT (4.3%).9 The numerical 
differences in ISTH major bleeding rates between AXAFA – AFNET 5 (apixaban 10 patients (3.1%); VKA 
14 patients (4.4%); Table 3) and RE-CIRCUIT (dabigatran 5 patients (1.6%); VKA 22 patients (6.9%))9 
could be due to chance variations in outcomes, differences in risk profile between the AXAFA – AFNET 
5 and RE-CIRCUIT study populations, and due to the high time in therapeutic range in the VKA group 
in AXAFA – AFNET 5 (median TTR 84%). AXAFA – AFNET 5 included only patients with stroke risk 
factors, resulting in a mean CHA2DS2VASc score of 2.4 and a population that was 4-5 years older than 
in the published controlled trials in atrial fibrillation ablation.1-3, 8, 9 Despite the higher stroke risk, we 
observed few strokes: AXAFA  - AFNET 5 found 2 strokes in 633 patients (0.3%), compared to 1 stroke 
in 248 patients in VENTURE-AF (0.4%)8, and 1 TIA in 635 patients in RE-CIRCUIT (0.2%)9. Equally, 
mortality was low (0.3%) and similar to VENTURE-AF (0.4%)8, RE-CIRCUIT (0%)9, and the EORP AF 
ablation registry (0.2%)25.  
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AXAFA – AFNET 5 included 86 patients on acenocoumarol and 102 patients on phenprocoumon, 186 
patients (29%) undergoing cryo-ablation3, and 84 patients undergoing atrial fibrillation ablation 
without transesophageal echocardiography without safety signals, providing some reassurance that 
these common patterns of clinical practice can be used on continuous apixaban or VKA therapy.4-6, 26  
 
The secondary outcomes observed in AXAFA – AFNET5 underpin the safety of continuous apixaban in 
atrial fibrillation ablation: time to ablation was not different between groups and quality of life and 
cognitive function improved equally in both study groups after ablation. High-resolution diffusion 
weighted brain MRI detected acute brain lesions at the expected rate (approximately 25%)12, 14, 15 without 
differences between study groups. Continuous anticoagulation does not fully prevent acute brain lesions, 
which can be caused by debris dislodging from ablation wounds, air emboli, or small thrombi.27, 28 
Procedural improvements are desirable to reduce acute brain lesions during atrial fibrillation ablation.29 
Further analyses of the AXAFA – AFNET 5 data set may shed more light on risk factors for acute brain 
lesions in patients undergoing AF ablation on continuous anticoagulation. One prior study found 
reduced cognitive function 90 days after atrial fibrillation ablation on interrupted warfarin therapy 
compared to baseline.10 Reassuringly, cognitive function improved at the end of AXAFA – AFNET 5 
without differences between study groups. 
 
Limitations.  
AXAFA – AFNET 5 was an open study, but with blinded outcome assessment. The non-inferoirity 
margin was wide. The findings are consistent with prior studies with continuous dabigatran and 
rivaroxaban. While AXAFA – AFNET 5 was the first study comparing cognitive function after atrial 
fibrillation ablation in a controlled trial, the assessment was limited to global cognitive function. 
Differentiation between acute and chronic lesions was done by using an accepted combination of MRI 
sequences. 14, 15 
 
Conclusions 
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Continuous apixaban therapy is a safe and effective alternative to VKA in patients at risk of stroke 
undergoing atrial fibrillation ablation with respect to stroke, major bleeding, cognitive function, and 
MRI-detected acute brain lesions.   
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Legends to Figures 
Figure 1: CONSORT diagram of the AXAFA – AFNET 5 study 
 
Figure 2A: Cumulative primary outcome events since randomization until 90 days after 
randomization at full scale (upper panel) and magnified (lower panel) in the ablation set. VKA vitamin 
K antagonist therapy.  
 
Figure 2B: Cumulative primary outcome events starting from ablation until 90 days after ablation at 
full scale (upper panel) and magnified (lower panel). VKA vitamin K antagonist therapy.    
 
Figure 3: Forest plot of the differences (90% confidence intervals) in event rates in the main clinical 
subgroups. VKA vitamin K antagonist therapy.    
 
Figure 4: Examples of acute brain lesions detected in the brain magnetic resonance imaging sub-
study. Acute brain lesions (arrows in Figures 4A, 4C, 4E, 4G) are found by high resolution diffusion 
weighted brain magnetic resonance imaging (DWI) without corresponding lesions in the Fluid-
attenuated inversion recovery (FLAIR) images (Figure 4B, 4D, 4F, 4H). Shown are representative 
lesions in two patients randomized to apixaban (Figure 4A/B; 4C/D) and in two patients randomized 
to VKA (Figure 4E/F; 4 G/H). The FLAIR images also detected chronic white matter lesions (asterisks 
(*) in Figure 4F). 
 
Summary Figure. Cumulative outcome events in AXAFA – AFNET 5 in patients undergoing atrial 
fibrillation ablation at risk of stroke (top) and comparison to event rates in the two other controlled trials 
comparing continuous NOAC therapy with continuous VKA therapy (bottom). TIMI major bleeds were 
not separately reported in the main paper of RE-CIRCUIT, ISTH major bleeds were not separately 
reported in the main paper of VENTURE-AF. 
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Table for apixaban in patients at risk of stroke undergoing AF ablation page 1 
Table 1: Inclusion and exclusion criteria of the AXAFA – AFNET 5 trial. Reproduced from 
the AXAFA – AFNET 5 design paper16. 
Inclusion Exclusion 
Non-valvular atrial fibrillation (ECG-
documented) with a clinical 
indication for catheter ablation 
Any disease that limits life expectancy to less than 1 year 
Clinical indication to undergo 
catheter ablation on continuous 
anticoagulant therapy 
Participation in another clinical trial, either within the past 
2 months or still ongoing 
Presence of at least one of the 
CHADS2 stroke risk factors*  
Previous participation in AXAFA 
Age ≥ 18 years Pregnant women or women of childbearing potential not on 
adequate birth control: only women with a highly effective 
method of contraception (oral contraception or intra-uterine 
device) or sterile women can be randomized 
Provision of signed informed 
consent 
Breastfeeding women 
Drug abuse or clinically manifest alcohol abuse 
Any stroke within 14 days before randomization 
Concomitant treatment with drugs that are strong dual 
inhibitors of cytochrome P450 3A4 (CYP3A4) and 
P-glycoprotein (P-gp) or strong dual inducers of CYP3A4 
and P-gp 
Valvular AF (as defined by the focused update of the ESC 
guidelines on AF, i.e. severe mitral valve stenosis, 
mechanical heart valve). Furthermore, patients who 
underwent mitral valve repair are not eligible for AXAFA 
Any previous ablation or surgical therapy for AF 
Cardiac ablation therapy for any indication (catheter-based 
or surgical) within 3 months prior to randomization 
Clinical need for “triple therapy” (combination therapy of 
clopidogrel, acetylsalicylic acid, and oral anticoagulation) 
Other contraindications for use of VKA or apixaban 
Documented atrial thrombi less than 3 months prior to 
randomization 
Severe chronic kidney disease with an estimated glomerular 
filtration rate (GFR) < 15 ml/min  
 
*Stroke or TIA, age ≥ 75 years, hypertension, defined as chronic treatment for 
hypertension, estimated need for continuous antihypertensive therapy or resting blood 
pressure > 145/90 mm Hg, diabetes mellitus, symptomatic heart failure (NYHA ≥ II). 
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Table for apixaban in patients at risk of stroke undergoing AF ablation page 2 
Table 2: Clinical characteristics of the AXAFA – AFNET 5 ablation population. 
Number of patients with valid information (n (%)) is only given when values were missing. 
BD twice daily dosing; SD standard deviation; q1, q3 are 25th and 75th percentiles, 
respectively; VKA vitamin K antagonist.  
 All patients Apixaban VKA 
 n=633 n=318 
(n=317 5 mg BD, 
n=1 2.5 mg BD) 
n=315 
(n=127 warfarin, 
n=102 
phenprocoumon, 
n=86 
acenocoumarol) 
Age (years) 
Median age (q1, q3)  64 (58, 70) 64 (57, 70) 64 (58, 70) 
Female sex 209 (33%) 100 (31%) 109 (35%) 
Weight (kg) 
Median weight (q1, q3) 87.0 (77.0, 99.3) 88.0 (77.0, 
100.0) 
86.6 (76.0, 98.0) 
Median Body Mass Index (q1, q3)  28.3 (25.3, 31.6) 28.4 (25.5, 31.3) 28.2 (25.2, 31.9) 
Concomitant conditions, stroke risk factors and CHA2DS2VASc score 
CHA2DS2VASc score, mean (SD) 2.4 (1.2) 2.4 (1.2) 2.4 (1.2) 
CHA2DS2VASc score, median (q1, 
q3)  
2 (2, 3)  2 (1, 3) 2 (2, 3) 
Hypertension (n) 571 (90.2%) 283 (89.0%) 288 (91.4%) 
Median systolic blood pressure (q1, 
q3) 
138.0 (125.0, 
150.0) 
137.0 (125.0, 
149.5) 
140.0 (125.0, 
152.0) 
Median diastolic blood pressure (q1, 
q3) 
82.0 (76.0, 
90.0) 
82.0 (75.0, 91.0) 82.0 (77.0, 90.0) 
Symptomatic heart failure (NYHA II-
IV) 
150 (23.7%) 78 (24.5%) 72 (22.9%) 
   NYHA I 62 (9.8%) 30 (9.4%) 32 (10.2%) 
   NYHA II 126 (19.9%) 67 (21.1%) 59 (18.7%) 
   NYHA III 24 (3.8%) 11 (3.5%) 13 (4.1%) 
   NYHA IV 0 0 0 
Diabetes mellitus 76 (12.0%) 41 (12.9%) 35 (11.1%) 
Prior stroke or transient ischemic 
attack 
47 (7.4%) 24 (7.5%) 23 (7.3%) 
Age ≥ 75 years 56 (8.8%) 28 (8.8%) 28 (8.9%) 
Age 65 – 74 years 240 (37.9%) 122 (38.4%) 118 (37.5%) 
Vascular disease, defined as coronary 
artery disease, peripheral artery 
disease, or carotid disease 
83 (13.1%) 41 (12.9%) 42 (13.3%) 
Valvular heart disease 73 (11.5%) 39 (12.3%) 34 (10.8%) 
Mitral valve disease (moderate or 
more) 
20 15 5 
Aortic valve disease (moderate or 
more) 
6 3 3 
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 All patients Apixaban VKA 
Confirmed coronary artery disease 77 (12.2%) 39 (12.3%) 38 (12.1%) 
Chronic obstructive lung disease 39 (6.2%) 21 (6.6%) 18 (5.7%) 
Clinical history of major bleeding 13 (2.1%) 10 (3.1%) 3 (1.0%) 
Concomitant medical therapy 
n (%) 633 318 315 
Amiodarone 102 (16.1%) 49 (15.4%) 53 (16.8%) 
Dronedarone 13 (2.1%) 3 (0.9%) 10 (3.2%) 
Flecainide 125 (19.7%) 59 (18.6%) 66 (21.0%) 
Propafenone 16 (2.5%) 8 (2.5%) 8 (2.5%) 
Sotalol >160mg/d 16 (2.5%) 7 (2.2%) 9 (2.9%) 
ACE inhibitor or angiotensin 
receptor blocker 
388 (61.3%) 192 (60.4%) 196 (62.2%) 
Calcium channel antagonists 147 (23.2%) 72 (22.6%) 75 (23.8%) 
Diuretics 221 (34.9%) 120 (37.7%) 101 (32.1%) 
Antianginal medication 2 (0.3%) 0 2 (0.6%) 
Antidiabetic medication 63 (10.0%) 32 (10.1%) 31 (9.8%) 
Statins 231 (36.5%) 111 (34.9%) 120 (38.1%) 
Platelet inhibitors or non-steroidal 
anti-inflammatory agents 
30 (4.7%) 11 (3.5%) 19 (6.0%) 
Beta blockers 451 (71.2%) 230 (72.3%) 221 (70.2%) 
Digoxin or digitoxin 26 (4.1%) 17 (5.3%) 9 (2.9%) 
Last INR before ablation  (n) 531 (83.9) 217 (68.2%) 314 (99.7%) 
Mean (SD) 1.9 (0.7) 1.2 (0.3), 
P<0.001 vs. VKA 
2.3 (0.5) 
Median (q1, q3) 2.0 (1.1, 2.4) 1.1 (1.0, 1.2) 
 
2.3 (2.0, 2.6) 
Quality of Life at baseline 
SF-12 physical component, n (%) 44.6 (37.7, 51.4), 
n=597 
43.5 (38.1, 51.3), 
n=301 
45.2 (37.6, 51.5), 
n=296 
SF-12 mental component n (%) 598 (94.5%) 301 (94.7%) 297 (94.3%) 
SF-12 mental component n (%) 50.3 (42.8, 
57.5), n=598 
51.2 (43.0, 57.9), 
n=301 
49.7 (42.6, 57.4), 
n=297 
    
Karnofsky scale 90 (80, 90) 
 
80 (80, 90) 
 
90 (80, 90) 
 
Cognitive function (Montreal Cognitive Assessment, MoCA) at baseline 
Median MoCA(q1, q3) 27.0 (25.0, 
29.0), n=618 
27.0 (25.0, 29.0), 
n=313 
27.0 (25.0, 
29.0), n=305 
At least mild cognitive impairment 
(MoCA <26) 
188 (30.4%) 93 (29.7%) 95 (31.1%) 
Modified EHRA scale at baseline 
mEHRA I 40 (6.3%) 18 (5.7%) 22 (7.0%) 
mEHRA IIa 164 (25.9%) 76 (23.9%) 88 (27.9%) 
mEHRA IIb 205 (32.4%) 107 (33.6%) 98 (31.1%) 
mEHRA III 208 (32.9%) 110 (34.6%) 98 (31.1%) 
mEHRA IV 16 (2.5%) 7 (2.2%) 9 (2.9%) 
Ablation information 
Atrial fibrillation pattern 
Paroxysmal atrial fibrillation 367 (58.0%) 189 (59.4%) 178 (56.5%) 
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 All patients Apixaban VKA 
Persistent or long-standing 
persistent atrial fibrillation 
266 (42.0%) 129 (40.6%) 137 (43.5%) 
Time from randomization to ablation (days) 
Mean (SD) 38.0 (27.3) 36.9 (27.6) 39.1 (27.0) 
Median (q1, q3) 35.0 (20.0, 
50.0) 
34.0 (18.0, 48.0) 36.0 (21.0, 52.0) 
Rhythm at start of ablation 
Number of patients 633 318 315 
Sinus rhythm 434 (68.6%) 212 (66.6%) 222 (70.6%) 
Atrial fibrillation 180 (28.4%) 98 (30.8%) 82 (26.0%) 
Atrial flutter 12 (1.9%) 3 (0.9%) 9 (2.8%) 
Pacing 7 (1.1%) 5 (1.6%) 2 (0.6%) 
Other  0 (0%)  0 (0%) 0 (0%) 
 
Type of ablation 
Pulmonary vein isolation, n (%) 571 (90.2%) 288 (90.6%) 283 (89.8%) 
Pulmonary vein isolation plus other 
ablation, n (%) 
59 (9.3%) 29 (9.1%) 30 (9.5%) 
Other ablation without pulmonary 
vein isolation 
3 (0.5%) 1 (0.3%) 2 (0.6%) 
Transesophageal echocardiography 
prior to ablation 
549 (86.7%) 269 (84.6%) 280 (88.9%) 
 
Total duration of ablation procedure 
(minutes), Median (q1, q3) 
135 (110, 175) 136 (110, 175) 135 (105, 172) 
Ablation energy source 
Radio frequency 402 (63.5%) 207 (65.1%) 195 (61.9%) 
Cryoablation 186 (29.3%) 92 (28.9%) 94 (29.8%) 
Other 45 (7.1%) 19 (6.0%) 26 (8.3%) 
Abnormal blood parameters 
Red blood cell count 
Abnormal 
65 / 618 (10.5%) 32 / 311 (10.3%) 33 / 307 (10.7%) 
Platelet count abnormal 35 / 625 (5.6%) 20 / 315 (6.3%) 15 / 310 (4.8%) 
ALT abnormal 75 / 612 (12.3%) 39 / 307 (12.7%) 36 / 305 (11.8%) 
Bilirubin abnormal 38 / 596 (6.4%) 14 / 297 (4.7%) 24 / 299 (8.0%) 
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Table 3: Primary outcomes in the AXAFA – AFNET 5 trial (ablation set), 
including details of the type of bleeding. Shown are number of patients per group. Some 
patients had more than one event. BARC4 events were not observed in the study. BD twice 
daily dosing.  
 All patients Apixaban VKA 
Patients with primary endpoint: 
composite of all-cause death, stroke or 
major bleeding 
45/633 (7.1%) 22/318 (6.9%), non-
inferiority p=0.0002 
23/315 (7.3%) 
Death 2 (0.3%) 1 (0.3%) 1 (0.3%) 
Stroke or TIA 2 (0.3%) 2 (0.6%) 0 
Major bleeding (BARC 2-5) 45 (7.1%) 20 (6.2%) 25 (7.9%) 
   Bleeding requiring medical attention 
(BARC 2) 
24 (3.8%) 12 (3.7%) 12 (3.8%) 
   Bleeding with hemoglobin drop of 30 
to <50 g/l or requiring transfusion 
(BARC 3a) 
9 (1.4%) 5 (1.6%) 4 (1.3%) 
   Bleeding with hemoglobin drop ≥50 
g/l, or requiring surgery or iv 
vasoactive agents, or cardiac 
tamponade (BARC 3b) 
11 (1.7%) 3 (0.9%) 8 (2.5%) 
   Intracranial hemorrhage (BARC 3c) 1 (0.2%) 0 1 (0.3%, fatal) 
TIMI major bleeding (Intracranial 
bleed, or bleeding resulting in a 
hemoglobin drop of ≥ 50 g/l, or bleeding 
resulting in death within 7 days) 
4 (0.6%) 1 (0.3%) 3 (1%) 
ISTH major bleeding 24 (3.8%) 10 (3.1%) 14 (4.4%) 
Bleeding event by clinical type 
Tamponade  7 (1.1%) 2 (0.6%) 5 (1.6%) 
Access site bleed 27 (4.3%) 12 (3.8%) 15 (4.8%) 
Bleeding requiring transfusion of red 
blood cells 
3 (0.5%) 2 (0.6%) 1 (0.3%) 
Other major bleed 7 (1.1%) 5 (1.6%) 2 (0.6%) 
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Table 4: Secondary outcomes in the AXAFA – AFNET 5 trial (ablation set). 
Number of patients with valid information (n (%)) is only given when values were 
missing. P values marked by asterisks (*) indicate differences between baseline and end 
of follow-up measurements. BD twice daily dosing; q1, q3 indicate25th and 75th 
percentiles, respectively.  
 All patients Apixaban VKA 
 n=633 n=318 
(n=317 5 mg BD, 
n=1 2.5 mg BD) 
n=315 
(n=127 warfarin, 
n=102 
phenprocoumon, 
n=86 
acenocoumarol) 
time from randomization to 
ablation in days, median 
(q1, q3) 
35.0 (20.0, 50.0) 34.0 (18.0, 48.0) 36.0 (21.0, 52.0) 
Nights spent in hospital 
after index ablation, 
median (q1, q3) 
3 (2, 5) 2 (1, 5) 3 (2, 7) 
ACT during ablation in 
seconds, median (q1, q3) 
325.0 (285.0, 
370.0) 
310.0 (273.0, 
350.0) 
348.5 (304.0, 
396.0) 
Number of subjects with all 
ACT values in range (n, %) 
234 / 631 (37.1%) 73 / 316 (23.1%) 161 / 315 (51.1%) 
Number of subjects with at 
least one ACT value < 250 
(n, %) 
214 / 631 (33.9%) 130 / 316 (41.1%) 84 / 315 (26.7%) 
Number of subjects with at 
least one ACT value < 300 
(n, %) 
397 / 631 (62.9%) 243 / 316 (76.9%) 154 / 315 (48.9%) 
Number of bleeding events 
(n) 
118 54 64 
Patients without recurrence 
of atrial fibrillation (n, %) 
434 / 619 (70.1%) 217 / 311 (69.8%) 217 / 308 (70.5%) 
Quality of life 
SF-12 physical component 
score at end of study, 
median (q1, q3), n 
48.6 (42.0, 54.2), 
n=564 
48.4 (41.9, 54.2), 
n=289 
48.8 (42.2, 54.4), 
n=275 
Change in SF-12 physical 
component score at end of 
study compared to baseline, 
median (q1, q3), n 
2.5 (-2.1, 8.1), 
n=547, p<0.001* 
2.4 (-2.2, 7.9), 
n=280 
2.8 (-2.0, 8.3), 
n=267 
SF-12 mental component 
score at end of study, 
median (q1, q3), n 
54.4 (46.0, 58.6), 
n=565 
54.2 (45.8, 58.3), 
n=290 
54.5 (46.6, 59.7), 
n=267 
Change in SF-12 mental 
component score at end of 
study compared to baseline, 
median (q1, q3), n  
1.2 (-3.2, 8.0), 
n=548, p<0.001* 
0.4 (-3.6, 8.0), 
n=281 
1.6 (-2.8, 8.3), 
n=267 
Karnofsky score at end of 
study, median (q1, q3), n 
100 (90, 100), 
n=619 
100 (90, 100), 
n=311 
100 (90, 100), 
n=308 
Change in Karnofsky score 
at end of study compared to 
10 (0, 10), n=619 10 (0, 10), n=311 10 (0, 10), n=308 
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baseline (Δ Karnofsky), 
median (q1, q3),  
Cognitive Function (Montreal Cognitive Assessment, MoCA) 
Cognitive function at end of 
study (MoCA), median (q1, 
q3), n 
28.0 (26.0, 29.0), 
n=607 
28.0 (26.0, 29.0), 
n=305 
28.0 (26.0, 29.0), 
n=302 
Abnormal MoCA at baseline 
(<26), n (%) 
141 (23.2%) 75 (24.6%) 66 (21.9%) 
Change in MoCA at end of 
study compared to baseline, 
Median (q1, q3), n 
1.0 (-1.0, 2.0), 
n=597, p<0.001* 
0.0 (-1.0, 2.0), 
n=301 
1.0 (-1.0, 2.0), 
n=296 
Change in patients with 
abnormal MoCA at end of 
study compared to baseline, 
n (%)  
141/607 (23.2%),  
-7.2%, p=0.005* 
75/305 (24.6%) 
-5.1% 
66/302 (21.9%) 
-9.2%  
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Table 5: Acute brain lesions detected by high resolution diffusion-weighted 
magnetic resonance imaging (MRI sub-study). P values were determined by 
Pearson’ s chi square text. 
 
 All 
patients 
(n=323) 
Apixaban  
(n=162) 
VKA 
 (n=161) 
P value 
No lesion 239 (74.0%) 118 (72.8%) 121 (75.2%) 0.635 
Exactly one lesion 46 (14.2%) 27 (16.7%) 19 (11.8%) 0.211 
Exactly two 
lesions 
21 (6.5%) 7 (4.3%) 14 (8.7%) 0.111 
More than two 
lesions 
17 (5.3%) 10 (6.2%) 7 (4.3%) 0.463 
 
 
 
Screened: 676
Randomized: 674
2 patients not eligible (exclusion criteria)
Allocated to Apixaban: 338 (ITT set) Allocated to VKA: 336 (ITT set)
10 did not receive study medication
7 declined continuation of study
1 left atrial thrombus
2 other reasons
9 did not receive study medication
6 declined continuation of study
2 left atrial thrombus
1 other reasons
328 received study drug (safety set) 327 received study drug (safety set)
318 underwent ablation (ablation set, mITT)
168 entered MRI substudy
162 analyzable MRI within 3-48 hours
6 had technically non-analyzable MRI
10 discontinued treatment before ablation
7 declined continuation of study 
1 left atrial thrombus
2 other reason
315 underwent ablation (ablation set, mITT)
167 entered MRI substudy
161 had analyzable MRI within 3-48 hours
6 had technically non-analyzable MRI
308 had final visit (320 had final call)
6 declined continuation of study 
0 lost to follow-up
1 death 
311 had final visit (324 had final call)
2 declined continuation of study
2 lost to follow-up
3 death or stroke
12 discontinued treatment before ablation
7 declined continuation of study 
2 left atrial thrombus
3 other reasons
Figure 1
 Figure 2A top panel
AXAFA-AFNET 5 
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Figure 4b 
Kaplan-Meier Cumulative Event Rate of Composite Primary Endpoint Magnified 
(mITT Population1) 
 
 
1mITT population: represents all randomized patients who underwent index catheter ablation 
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Figure 4g 
Kaplan-Meier Cumulative Event Rate of Composite Primary Endpoint 
(mITT Population1) 
 
 
1mITT population: represents all randomized patients who underwent index catheter ablation 
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Figure 4h 
Kaplan-Meier Cumulative Event Rate of Composite Primary Endpoint Magnified 
(mITT Population1) 
 
 
1mITT population: represents all randomized patients who underwent index catheter ablation 
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Figure 5 
Forest Plot of Primary Composite Event Rate Differences with Respect to Covariate Subgroups 
(mITT Population1) 
 
 
1mITT population: represents all randomized patients who underwent index catheter ablation  
287.0 kg is the median weight in the ITT population 
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Figure 3
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Figure 4
Cumulative Outcome Events in AXAFA – AFNET 5 (top) and event 
rates in the patients undergoing ablation the three trials comparing 
continuous NOAC to VKA in AF ablation patients (bottom)
TIMI major bleeds were not reported in RE-CIRCUIT
ISTH major bleeds were not reported in VENTURE-AF
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